NuCana Appoints Theresa Bruce as Chief Operating Officer

Core Viewpoint - NuCana plc has appointed Theresa Bruce as Chief Operating Officer, effective January 1, 2026, to enhance its leadership team and advance its clinical pipeline focused on cancer treatment [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes through its ProTide technology, which aims to transform conventional chemotherapy agents into more effective and safer medicines [3]. - The company’s pipeline includes NUC-7738, a novel anti-cancer agent currently in a Phase 1/2 study, and NUC-3373, derived from the widely used chemotherapy agent 5-fluorouracil [3]. Leadership Appointment - Theresa Bruce brings over 25 years of experience in oncology research and development, having held senior leadership roles in various biotechnology companies and clinical research organizations [2]. - Her operational leadership is expected to be crucial for advancing NuCana's pipeline, particularly for NUC-7738 and NUC-3373, and for preparing registration strategies for potential marketing approvals [2]. Strategic Focus - The company aims to generate data in 2026 from the Phase 1/2 expansion study of NUC-7738 in combination with pembrolizumab for melanoma patients [2]. - NuCana anticipates a cash runway extending into 2029, which will support its ongoing clinical studies and development efforts [2].